Stride Velocity 95 th Centile Detects Decline in Ambulatory Function Over Shorter Intervals than the 6-Minute Walk Test or North Star Ambulatory Assessment in Duchenne Muscular Dystrophy
Michael Rabbia; Maitea Guridi Ormazabal; Hannah Staunton; Klaas Veenstra; Damien Eggenspieler; M. Annoussamy; Laurent Servais; Paul Strijbos · 2024 · Journal of Neuromuscular Diseases
WASTE classifies this as Negative / Null Result Report · AI classification, approximate
The study found no significant effect — useful as a negative control or null benchmark for your own design.
Abstract
Background: Stride Velocity 95th Centile (SV95C) is the first wearable device-derived clinical outcome assessment (COA) to receive European Medicines Agency (EMA) qualification as a primary endpoint in ambulant patients with Duchenne muscular dystrophy (DMD) aged ≥4 years. Objective: To compare SV95C-in its first-ever clinical trial application as a secondary endpoint-with established motor function COAs used in the trial (Four-Stair Climb [4SC] velocity, North Star Ambulatory Assessment [NSAA], and Six-Minute Walk Distance [6MWD]). Methods: SV95C was a secondary endpoint in a subset (n = 47)
Abstract by Michael Rabbia; Maitea Guridi Ormazabal; Hannah Staunton; Klaas Veenstra; Damien Eggenspieler; M. Annoussamy; Laurent Servais; Paul Strijbos, Journal of Neuromuscular Diseases (2024) — licensed CC BY 4.0.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
Power and Predictive Accuracy of Polygenic Risk Scores
Negative / Null Result ReportLocoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases
Negative / Null Result ReportCritical aspects of using bacterial cell viability assays with the fluorophores SYTO9 and propidium iodide
Negative / Null Result ReportAlpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
Negative / Null Result ReportA randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy
Negative / Null Result ReportThe CAFA challenge reports improved protein function prediction and new functional annotations for hundreds of genes through experimental screens
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: OpenAlex · DOI 10.3233/jnd-230188